Article
Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy.
Annals of surgical oncology - 1 Dec 2014
Alakus Hakan, Bollschweiler Elfriede, Hölscher Arnulf H, Warnecke-Eberz Ute, Frazer Kelly A, Harismendy Olivier, Lowy Andrew M, Mönig Stefan P, Eberz Pascal M, Maus Martin, Drebber Uta, Siffert Winfried, Metzger Ralf
Abstract excerpt
BACKGROUND: Currently, patients with locally advanced esophageal cancer receive neoadjuvant chemoradiotherapy but only about half of these patients benefit from this treatment. GNAS T393C has been shown to predict the postoperative course in solid tumors and may therefore be useful for treatment stratification. The aim of the present study was to determine if the single-nucleotide polymorphism GNAS T393C can be...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.